Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2013 1
2014 5
2015 11
2016 39
2017 79
2018 70
2019 116
2020 130
2021 140
2022 133
2023 148
2024 51

Text availability

Article attribute

Article type

Publication date

Search Results

826 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA, DiNardo C, Konopleva M. Guerra VA, et al. Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. Best Pract Res Clin Haematol. 2019. PMID: 31203996 Free PMC article. Review.
Clinical trials have demonstrated the clinical benefit of venetoclax-based therapies in newly diagnosed AML, leading to the recent FDA approval of venetoclax in combination with hypomethylating agents or low-dose cytarabine for older adults with newly diagnosed AML. …
Clinical trials have demonstrated the clinical benefit of venetoclax-based therapies in newly diagnosed AML, leading to the recent FD …
Venetoclax resistance: mechanistic insights and future strategies.
Ong F, Kim K, Konopleva MY. Ong F, et al. Cancer Drug Resist. 2022 May 6;5(2):380-400. doi: 10.20517/cdr.2021.125. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35800373 Free PMC article. Review.
In this review, we will provide a comprehensive summary of the known mechanisms of resistance to Venetoclax and discuss Venetoclax-based combination therapies. Key contributing factors to Venetoclax resistance include dependencies on alternative anti-apoptoti …
In this review, we will provide a comprehensive summary of the known mechanisms of resistance to Venetoclax and discuss Venetoclax …
Venetoclax.
[No authors listed] [No authors listed] 2020 Dec 21. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Dec 21. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33355735 Free Books & Documents. Review.
No information is available on the use of venetoclax during breastfeeding. Because venetoclax is more than 99% bound to plasma proteins, the amount in milk is likely to be low. ...
No information is available on the use of venetoclax during breastfeeding. Because venetoclax is more than 99% bound to plasma …
Venetoclax in adult acute myeloid leukemia.
Hu M, Li W, Zhang Y, Liang C, Tan J, Wang Y. Hu M, et al. Biomed Pharmacother. 2023 Dec;168:115820. doi: 10.1016/j.biopha.2023.115820. Epub 2023 Nov 6. Biomed Pharmacother. 2023. PMID: 37925935 Free article. Review.
Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. ...In this review, we provide an overview of …
Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in …
Review of Venetoclax in CLL, AML and Multiple Myeloma.
Lasica M, Anderson MA. Lasica M, et al. J Pers Med. 2021 May 24;11(6):463. doi: 10.3390/jpm11060463. J Pers Med. 2021. PMID: 34073976 Free PMC article. Review.
Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. ...Based on data from MURANO and CLL14 studies, fixed-duration combination therapy of venetoclax with anti-CD20 an …
Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potentia …
Venetoclax.
[No authors listed] [No authors listed] 2017 Apr 4. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Apr 4. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643779 Free Books & Documents. Review.
Venetoclax is an oral selective BCL-2 inhibitor and antineoplastic agent used in the therapy of refractory chronic lymphocytic leukemia (CLL). ...Venetoclax has potent immunosuppressive activity and may be capable of causing reactivation of hepatitis B....
Venetoclax is an oral selective BCL-2 inhibitor and antineoplastic agent used in the therapy of refractory chronic lymphocytic leukem …
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Dhakal P, Bates M, Tomasson MH, Sutamtewagul G, Dupuy A, Bhatt VR. Dhakal P, et al. Blood Rev. 2023 May;59:101036. doi: 10.1016/j.blre.2022.101036. Epub 2022 Dec 1. Blood Rev. 2023. PMID: 36549969 Review.
Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with a DNA hypomethylating agent or low dose cytarabine, results in high rates of initial responses in patients with acute myeloid leukemia (AML). ...Current clinical trials are exploring …
Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with a DNA hypomethylating agent or low dose cy …
Venetoclax-containing regimens in acute myeloid leukemia.
Aldoss I, Pullarkat V, Stein AS. Aldoss I, et al. Ther Adv Hematol. 2021 Feb 11;12:2040620720986646. doi: 10.1177/2040620720986646. eCollection 2021. Ther Adv Hematol. 2021. PMID: 33628408 Free PMC article. Review.
Thus, the introduction of venetoclax has transformed the landscape of AML therapy in elderly patients. ...Here, we review clinical data for venetoclax-based therapy in AML, both from prospective as well as retrospective studies, and highlight ongoing novel studies o …
Thus, the introduction of venetoclax has transformed the landscape of AML therapy in elderly patients. ...Here, we review clinical da …
Venetoclax in Acute Myeloid Leukemia.
Mihăilă RG. Mihăilă RG. Recent Pat Anticancer Drug Discov. 2023;18(1):11-28. doi: 10.2174/1574892817666220429105338. Recent Pat Anticancer Drug Discov. 2023. PMID: 35507786 Review.
OBJECTIVE: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia. METHODS: A mini-review was achieved using the articles published in PubMed and Web of Science in the last year, prior to 05.05.2021, which were …
OBJECTIVE: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia. METH …
Mechanisms of venetoclax resistance and solutions.
Liu J, Chen Y, Yu L, Yang L. Liu J, et al. Front Oncol. 2022 Oct 12;12:1005659. doi: 10.3389/fonc.2022.1005659. eCollection 2022. Front Oncol. 2022. PMID: 36313732 Free PMC article. Review.
The BCL-2 inhibitor venetoclax is currently approved for treatment of hematologic diseases and is widely used either as monotherapy or in combination strategies. It has produced promising results in the treatment of refractory or relapsed (R/R) and aged malignant hematolog …
The BCL-2 inhibitor venetoclax is currently approved for treatment of hematologic diseases and is widely used either as monotherapy o …
826 results